Clovis Oncology Inc. (NASDAQ:CLVS) saw an upside of 0.46% to close Tuesday at $4.33 after adding $0.02 on the day. The 5-day average trading volume is 1,634,760 shares of the company’s common stock. It has gained $4.50 in the past week. An average of 2,722,265 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,938,298.
CLVS’s 1-month performance is 0.00% or -$0.03 on its low of $4.23 reached on 09/14/21. The company’s shares have touched a 52-week low of $4.06 and high of $11.10, with the stock’s rally to the 52-week high happening on 02/08/21. YTD, CLVS has lost -9.79% or -$0.47. However, the current price is down -60.99%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Oct 04, 9 days have gone by since the last insider trading activity for Clovis Oncology Inc. (CLVS). Harding Thomas C. (See Remarks) most recently sold 6 shares at $4.41 per share on Oct 04. This transaction cost the insider $26. See Remarks, IVERS-READ GILLIAN C, sold 304 shares at a price of $4.89 on Sep 02. Then, on Sep 02, See Remarks Rolfe Lindsey sold 347 shares at a price of $4.89 per share. This transaction amounted to $1,697.
Clovis Oncology Inc. (CLVS) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector.CLVS stock has a beta of 1.71. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.30.
Clovis Oncology Inc.’s quick ratio for the period ended June 29 was 1.60, with the current ratio over the same period at 1.70 meaning that CLVS stock is able to fulfill its debt obligations. In terms of profitability, the gross margin trailing 12 months is 74.60%. The trailing 12-month EBITDA margin is -178.69%. The firm’s gross profit as reported stood at $123.22 million against revenue of $164.52 million.
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -8.34% to $36.82 million, while revenue of $38.05 million was -3.34% off the previous quarter. Analysts expected CLVS to announce -$0.56 per share in earnings in its latest quarter, but it posted -$0.61, representing a -8.90% surprise. EBITDA for the quarter stood at more than -$54.72 million. CLVS stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 779.21 million, with total debt at $672.63 million. Shareholders hold equity totaling $118.41 million
Let’s look briefly at Clovis Oncology Inc. (CLVS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 41.83% to suggest the stock is trending Neutral, with historical volatility in this time period at 32.37%.
The stock’s 5-day moving average is $4.34, reflecting a -0.23% or -$0.01 change from its current price. CLVS is currently trading +1.17% above its 20-day SMA, -17.99% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -11.99% and -11.27% respectively.
Stochastic %K and %D was 14.19% and 16.67% and the average true range (ATR) pointed at 0.17. The RSI (14) points at 43.33%, while the 14-day stochastic is at 13.69% with the period’s ATR at 0.18. The stock’s 9-day MACD Oscillator is pointing at -0.03 and -0.14 on the 14-day charts.
In the most recent analyst report for Clovis Oncology Inc. (NASDAQ: CLVS), H.C. Wainwright reiterated its a Buy rating for the company but lifted their price target by $29 to $33. Analysts offering their rating for CLVS stock have a consensus rating for the stock as Underweight. Currently, 2 brokerage advisors rate CLVS as a “sell,”, while 2 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is CLVS’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $3.00 and a high of $9.00, with their median price target at $5.50. Looking at these predictions, the average price target given by analysts is for Clovis Oncology Inc. (CLVS) stock is $5.70.